David A. Hyman, MD, JD, on Inclusive Shared Savings

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Welcome and Introduction to Vi3C

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Nov

Today In Oncology

David A. Hyman, MD, JD, on Inclusive Shared Savings

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Welcome and Introduction to Vi3C

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Basser Center for BRCA Awards 2026 Global Prize

Triplet Therapy With Abiraterone Improves OS Long-Term in Metastatic Castration-Sensitive Prostate Cancer

Phase III VOLGA Trial Explores Outcomes in Muscle Invasive Bladder Cancer

First-Line Pembrolizumab Improves Progression-Free Survival in dMMR Advanced Endometrial Cancer

Bispecific ADC May Offer New Treatment Option for HR-Positive, HER2-Negative Breast Cancer